Steven C Schallhorn,1–3 Jan A Venter,2 David Teenan,2 Julie M Schallhorn,3 Keith A Hettinger,2 Stephen J Hannan,2 Martina Pelouskova2 1Department of Ophthalmology, University of California, San Francisco, CA, USA; 2Optical Express, Glasgow, UK; 3Department of Ophthalmology, University of Southern California, Los Angeles, CA, USA Purpose: The aim of this study was to assess visual and refractive outcomes of laser vision correction (LVC) to correct residual refraction after multifocal intraocular lens (IOL) implantation.Patients and methods: Loveseat In this retrospective study, 782 eyes that underwent LVC to correct unintended ametropia after multifocal IOL implantation were evaluated.Of all multifocal lenses implanted during primary procedure, 98.7% were refractive and 1.
3% had a diffractive design.All eyes were treated with VISX STAR S4 IR excimer laser using a convectional ablation profile.Refractive outcomes, visual acuities, patient satisfaction, and quality of life were evaluated at the last available visit.Results: The mean time between enhancement and last visit was 6.
3±4.4 months.Manifest spherical equivalent changed from -0.02±0.
83 D (-3.38 D to +2.25 D) pre-enhancement to 0.00±0.
34 D (-1.38 D to +1.25 D) post-enhancement.At the last follow-up, the percentage of eyes within 0.
50 D and 1.00 D of emmetropia was 90.4% and 99.5%, respectively.
Of all eyes, 74.9% achieved monocular uncorrected distance visual acuity 20/20 or better.The BERRYBLAST MINTS mean corrected distance visual acuity remained the same before (-0.04±0.
06 logMAR [logarithm of the minimum angle of resolution]) and after LVC procedure (-0.04±0.07 logMAR; P=0.70).
There was a slight improvement in visual phenomena (starburst, halo, glare, ghosting/double vision) following the enhancement.No sight-threatening complications related to LVC occurred in this study.Conclusion: LVC in pseudophakic patients with multifocal IOL was safe, effective, and predictable in a large cohort of patients.Keywords: excimer laser enhancements, pseudophakic patients, multifocal IOL.